{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T20:48:50Z","timestamp":1793479730791,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s40257-022-00730-y","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T09:03:55Z","timestamp":1664355835000},"page":"15-24","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["What\u2019s New in Therapy for Male Androgenetic Alopecia?"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6315-5462","authenticated-orcid":false,"given":"David","family":"Saceda-Corralo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0560-7023","authenticated-orcid":false,"given":"Miguel","family":"Dom\u00ednguez-Santas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7494","authenticated-orcid":false,"given":"Sergio","family":"Va\u00f1\u00f3-Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7204-8626","authenticated-orcid":false,"given":"Ramon","family":"Grimalt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"issue":"2","key":"730_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1046\/j.1365-2133.2001.04018.x","volume":"144","author":"MP Birch","year":"2001","unstructured":"Birch MP, Messenger JF, Messenger AG. Hair density, hair diameter and the prevalence of female pattern hair loss. Br J Dermatol. 2001;144(2):297\u2013304.","journal-title":"Br J Dermatol"},{"issue":"2","key":"730_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.jaad.2004.04.008","volume":"52","author":"EA Olsen","year":"2005","unstructured":"Olsen EA, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301\u201311.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"730_CR3","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1440-0960.2011.00745.x","volume":"52","author":"L Yip","year":"2011","unstructured":"Yip L, Rufaut N, Sinclair R. Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know. Australas J Dermatol. 2011;52(2):81\u20138.","journal-title":"Australas J Dermatol"},{"issue":"3","key":"730_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/exd.12024","volume":"22","author":"S Inui","year":"2013","unstructured":"Inui S, Itami S. Androgen actions on the human hair follicle: perspectives. Exp Dermatol. 2013;22(3):168\u201371.","journal-title":"Exp Dermatol"},{"issue":"2","key":"730_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jaad.2009.09.018","volume":"63","author":"HC Eun","year":"2010","unstructured":"Eun HC, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010;63(2):252\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"730_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.jaad.2013.10.049","volume":"70","author":"W GubelinHarcha","year":"2014","unstructured":"GubelinHarcha W, et al. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489\u201398.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"730_CR7","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jaad.2006.05.007","volume":"55","author":"EA Olsen","year":"2006","unstructured":"Olsen EA, et al. The importance of dual 5\u03b1-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014\u201323.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"730_CR8","first-page":"703","volume":"79","author":"AL Dallob","year":"1994","unstructured":"Dallob AL, et al. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab. 1994;79(3):703\u20136.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"730_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamadermatol.2021.5743","volume":"158","author":"AK Gupta","year":"2022","unstructured":"Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-\u03b1 reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatol. 2022;158(3):266\u201374.","journal-title":"JAMA Dermatol"},{"key":"730_CR10","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/CIA.S192435","volume":"14","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Song S, Gao Z, Wu J, Ma J, Cui Y. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clin Interv Aging. 2019;14:399\u2013406.","journal-title":"Clin Interv Aging"},{"issue":"3","key":"730_CR11","first-page":"1496","volume":"282","author":"HN Bramson","year":"1997","unstructured":"Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK, Frye SV. Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. J Pharmacol Exp Ther. 1997;282(3):1496\u2013502.","journal-title":"J Pharmacol Exp Ther"},{"key":"730_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13182","volume":"33","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2020","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study. Dermatol Ther. 2020;33: e13182.","journal-title":"Dermatol Ther"},{"key":"730_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.03.037","author":"DD Nguyen","year":"2022","unstructured":"Nguyen DD, et al. Disproportional signal of sexual dysfunction reports associated with finasteride use in young men with androgenetic alopecia: a pharmacovigilance analysis of VigiBase. J Am Acad Dermatol. 2022. https:\/\/doi.org\/10.1016\/j.jaad.2022.03.037.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"730_CR14","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/j.1743-6109.2011.02255.x","volume":"8","author":"MS Irwig","year":"2011","unstructured":"Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747\u20132175.","journal-title":"J Sex Med"},{"issue":"1","key":"730_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.7241\/ourd.20131.08","volume":"4","author":"N Sobhy","year":"2013","unstructured":"Sobhy N, Aly H, El Shafee A, El Deeb M. Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatol. 2013;4(1):40\u20135.","journal-title":"Our Dermatol"},{"issue":"1","key":"730_CR16","first-page":"137","volume":"20","author":"M Abdallah","year":"2009","unstructured":"Abdallah M, Khaled E-Z, Hanan B. Mesotherapy using dutasteride-containing solution in male pattern hair loss: a controlled pilot study. J Pan-Arab Leag Dermatol. 2009;20(1):137\u201345.","journal-title":"J Pan-Arab Leag. Dermatol."},{"issue":"6","key":"730_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000510697","volume":"6","author":"ME Herz-Ruelas","year":"2020","unstructured":"Herz-Ruelas ME, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Ski Appendage Disord. 2020;6(6):338\u201345.","journal-title":"Ski Appendage Disord."},{"issue":"6","key":"730_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1468-3083.2012.04535.x","volume":"27","author":"N Moftah","year":"2013","unstructured":"Moftah N, et al. Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrustructural evaluation. J Eur Acad Dermatology Venereol. 2013;27(6):686\u201393.","journal-title":"J Eur Acad Dermatology Venereol."},{"issue":"3","key":"730_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4103\/ijt.ijt_73_16","volume":"9","author":"D Saceda-Corralo","year":"2017","unstructured":"Saceda-Corralo D, Rodrigues-Barata A, Vano-Galvan S, Jaen-Olasolo P. Mesotherapy with dutasteride in the treatment of androgenetic alopecia. Int J Trichology. 2017;9(3):143.","journal-title":"Int J Trichology."},{"issue":"7","key":"730_CR20","first-page":"742","volume":"21","author":"D Saceda-Corralo","year":"2022","unstructured":"Saceda-Corralo D, Moustafa F, Moreno-Arrones \u00d3M, Jaen-Olasolo P, Camacho FM. Mesotherapy with dutasteride for androgenetic alopecia: a retrospective study in real clinical practice. J Drugs Dermatol. 2022;21(7):742\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"730_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15247","volume":"35","author":"DF Melo","year":"2022","unstructured":"Melo DF, et al. Frontal edema due to mesotherapy for androgenetic alopecia: a case series. Dermatol Ther. 2022;35(2): e15247.","journal-title":"Dermatol Ther"},{"key":"730_CR22","unstructured":"Loniten (Minoxidil Tablets USP). Pharmacia & Upjohn Company LLC. Kirkland: Pfizer Canada Inc.; 2013."},{"issue":"2","key":"730_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jaad.2019.04.054","volume":"81","author":"J Jimenez-Cauhe","year":"2019","unstructured":"Jimenez-Cauhe J, et al. Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia. J Am Acad Dermatol. 2019;81(2):648\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"730_CR24","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.jaad.2019.08.085","volume":"82","author":"J Jimenez-Cauhe","year":"2020","unstructured":"Jimenez-Cauhe J, Saceda-Corralo D, Moreno-Arrones OM, Ortega-Quijano D, Fernandez-Nieto D, Va\u00f1o-Galvan S. Reply to: \u2018Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation.\u2019 J Am Acad Dermatol. 2020;82(1):e23\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"730_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2015.02.466","volume":"72","author":"S Lueangarun","year":"2015","unstructured":"Lueangarun S, Panchaprateep R, Tempark T. Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. J Am Acad Dermatol. 2015;72(5):113.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"730_CR26","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.jaad.2019.08.084","volume":"82","author":"R Pirmez","year":"2019","unstructured":"Pirmez R, Salas-Callo CI. Very low dose oral minoxidil in male androgenetic alopecia: a study with quantitative trichoscopic documentation. J Am Acad Dermatol. 2019;82(1):e21\u20132.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"730_CR27","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s13555-020-00448-x","volume":"10","author":"R Panchaprateep","year":"2020","unstructured":"Panchaprateep R, Lueangarun S. Efficacy and safety of oral minoxidil 5 mg once daily in the treatment of male patients with androgenetic alopecia: an open-label and global photographic assessment. Dermatol Ther (Heidelb). 2020;10(6):1345\u201357.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10","key":"730_CR28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/jdv.12362","volume":"28","author":"MJ Harries","year":"2014","unstructured":"Harries MJ, Messenger A. Treatment of frontal fibrosing alopecia and lichen planopilaris. J Eur Acad Dermatol Venereol. 2014;28(10):1404\u20135.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"730_CR29","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/j.jaad.2021.02.054","volume":"84","author":"S Va\u00f1\u00f3-Galv\u00e1n","year":"2021","unstructured":"Va\u00f1\u00f3-Galv\u00e1n S, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644\u201351.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"730_CR30","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jaad.2020.11.035","volume":"84","author":"B Sanabria","year":"2021","unstructured":"Sanabria B, Miot HA, M\u00fcller P, Ramos. Adverse effects of low-dose oral minoxidil for androgenetic alopecia in 435 patients. J Am Acad Dermatol. 2021;84(4):1175\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"730_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jaad.2020.08.124","volume":"84","author":"J Jimenez-Cauhe","year":"2021","unstructured":"Jimenez-Cauhe J, et al. Characterization and management of hypertrichosis induced by low-dose oral minoxidil in the treatment of hair loss. J Am Acad Dermatol. 2021;84(1):222\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"730_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jaad.2015.02.466","volume":"72","author":"S Lueangarun","year":"2015","unstructured":"Lueangarun S, Panchaprateep R, Tempark T, Noppakun N. Efficacy and safety of oral minoxidil 5 mg daily during 24-week treatment in male androgenetic alopecia. J Am Acad Dermatol. 2015;72(5):113.","journal-title":"J Am Acad Dermatol"},{"key":"730_CR33","doi-asserted-by":"publisher","first-page":"e14106","DOI":"10.1111\/dth.14106","volume":"33","author":"J Jimenez-Cauhe","year":"2020","unstructured":"Jimenez-Cauhe J, et al. Safety of low-dose oral minoxidil treatment for hair loss A systematic review and pooled-analysis of individual patient data. Dermatol Ther. 2020;33:e14106.","journal-title":"Dermatol Ther"},{"issue":"1","key":"730_CR34","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1111\/jdv.17623","volume":"36","author":"L Bokhari","year":"2022","unstructured":"Bokhari L, Jones LN, Sinclair RD. Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial. J Eur Acad Dermatology Venereol. 2022;36(1):e62\u20136.","journal-title":"J Eur Acad Dermatology Venereol."},{"issue":"4","key":"730_CR35","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1529-8019.2011.01441.x","volume":"24","author":"A Rossi","year":"2011","unstructured":"Rossi A, Cantisani C, Scarn\u00f2 M, Trucchia A. Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatol Ther. 2011;24(4):455\u201361.","journal-title":"Dermatol Ther"},{"issue":"5","key":"730_CR36","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1001\/jamainternmed.2017.0089","volume":"177","author":"B Welk","year":"2017","unstructured":"Welk B, McArthur E, Ordon M, Anderson KK, Hayward J, Dixon S. Association of suicidality and depression with 5\u03b1-reductase inhibitors. JAMA Intern Med. 2017;177(5):683.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"730_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3109\/09546639709160517","volume":"8","author":"GF Mazzarella","year":"1997","unstructured":"Mazzarella GF, Loconsole GF, Cammisa GA, Mastrolonardo GM, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatolog Treat. 1997;8(3):189\u201392.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"730_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5414\/CP202467","volume":"54","author":"M Caserini","year":"2016","unstructured":"Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19\u201327.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"10","key":"730_CR39","doi-asserted-by":"publisher","first-page":"842","DOI":"10.5414\/CP202119","volume":"52","author":"M Caserini","year":"2014","unstructured":"Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"18","key":"730_CR40","first-page":"2017","volume":"164","author":"BM Piraccini","year":"2021","unstructured":"Piraccini BM, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. J Eur Acad Dermatology Venereol. 2021;164(18):2017\u201323.","journal-title":"J. Eur. Acad. Dermatology Venereol."},{"issue":"10","key":"730_CR41","first-page":"1312","volume":"95","author":"C Tanglertsampan","year":"2012","unstructured":"Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil\/0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95(10):1312\u20136.","journal-title":"J Med Assoc Thai"},{"issue":"1","key":"730_CR42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.4103\/2229-5178.148925","volume":"6","author":"B Chandrashekar","year":"2015","unstructured":"Chandrashekar B, Nandhini T, Vasanth V, Sriram R, Navale S. Topical minoxidil fortified with finasteride: an account of maintenance of hair density after replacing oral finasteride. Indian Dermatol Online J. 2015;6(1):17.","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"730_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000477353","volume":"4","author":"R Alves","year":"2018","unstructured":"Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Ski Appendage Disord. 2018;4(1):18\u201324.","journal-title":"Ski Appendage Disord."},{"issue":"2","key":"730_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms18020408","volume":"18","author":"P Gentile","year":"2017","unstructured":"Gentile P, et al. Evaluation of not-activated and activated PRP in hair loss treatment: role of growth factor and cytokine concentrations obtained by different collection systems. Int J Mol Sci. 2017;18(2):1\u201316.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"730_CR45","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaad.2018.03.022","volume":"82","author":"A Ho","year":"2020","unstructured":"Ho A, Sukhdeo K, Lo Sicco K, Shapiro J. Trichologic response of platelet-rich plasma in androgenetic alopecia is maintained during combination therapy. J Am Acad Dermatol. 2020;82(2):478\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"730_CR46","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/DSS.0000000000000665","volume":"42","author":"R Alves","year":"2016","unstructured":"Alves R, Grimalt R. Randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg. 2016;42(4):491\u20137.","journal-title":"Dermatol Surg"},{"issue":"1","key":"730_CR47","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/DSS.0000000000001198","volume":"44","author":"R Alves","year":"2018","unstructured":"Alves R, Grimalt R. Platelet-rich plasma in combination with 5% minoxidil topical solution and 1 mg oral finasteride for the treatment of androgenetic alopecia: a randomized placebo-controlled, double-blind Half-Head Study. Dermatol Surg. 2018;44(1):126\u201330.","journal-title":"Dermatol Surg"},{"issue":"2","key":"730_CR48","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10103-015-1818-2","volume":"31","author":"M Zarei","year":"2016","unstructured":"Zarei M, Wikramanayake TC, Falto-Aizpurua L, Schachner LA, Jimenez JJ. Low level laser therapy and hair regrowth: an evidence-based review. Lasers Med Sci. 2016;31(2):363\u201371.","journal-title":"Lasers Med Sci"},{"issue":"5","key":"730_CR49","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jaad.2017.11.040","volume":"78","author":"P Fonda-Pascual","year":"2018","unstructured":"Fonda-Pascual P, et al. Effectiveness of low-level laser therapy in lichen planopilaris. J Am Acad Dermatol. 2018;78(5):1020\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"730_CR50","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1007\/s10103-022-03520-4","volume":"37","author":"J Qiu","year":"2022","unstructured":"Qiu J, et al. Efficacy assessment for low-level laser therapy in the treatment of androgenetic alopecia: a real-world study on 1383 patients. Lasers Med Sci. 2022;37(6):2589\u201394.","journal-title":"Lasers Med Sci"},{"issue":"5","key":"730_CR51","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2165\/00044011-200929050-00001","volume":"29","author":"M Leavitt","year":"2009","unstructured":"Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb? Laser phototherapy device in the treatment of male androgenetic alopecia a randomized, double-blind, sham device-controlled, multicentre trial matt. Clin Drug Invest. 2009;29(5):283\u201392.","journal-title":"Clin Drug Invest"},{"issue":"8","key":"730_CR52","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1111\/dsu.12200","volume":"39","author":"H Kim","year":"2013","unstructured":"Kim H, Choi JW, Kim JY, Shin JW, Lee SJ, Huh CH. Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device-controlled multicenter trial. Dermatologic Surg. 2013;39(8):1177\u201383.","journal-title":"Dermatologic Surg"},{"issue":"1","key":"730_CR53","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jaad.2017.02.054","volume":"77","author":"A Adil","year":"2017","unstructured":"Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5.","journal-title":"J Am Acad Dermatol"},{"key":"730_CR54","unstructured":"Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration. ClinicalTrials.gov. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT04984707?term=pyrilutamide&draw=2&rank=1. Accessed 23 Feb 2022."},{"key":"730_CR55","unstructured":"Kintor Pharmaceutical Receives IND Clearance by the U.S. FDA for GT20029 to Treat Androgenetic Alopecia and Acne. Kintor Pharmaceutical Limited. Available at: https:\/\/en.kintor.com.cn\/news\/181.html. Accessed 23 Feb 2022."},{"issue":"2","key":"730_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/09546634.2017.1341610","volume":"29","author":"A Rossi","year":"2018","unstructured":"Rossi A, et al. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatol Treat. 2018;29(2):149\u201351.","journal-title":"J Dermatol Treat"},{"key":"730_CR57","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2147\/CCID.S319676","volume":"14","author":"J Dubois","year":"2021","unstructured":"Dubois J, et al. Setipiprant for androgenetic alopecia in males: results from a randomized, double-blind, placebo-controlled phase 2a trial. Clin Cosmet Investig Dermatol. 2021;14:1507\u201317.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"6","key":"730_CR58","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/j.jaad.2020.04.082","volume":"83","author":"U Shon","year":"2020","unstructured":"Shon U, Kim MH, Lee DY, Kim SH, Park BC. The effect of intradermal botulinum toxin on androgenetic alopecia and its possible mechanism. J Am Acad Dermatol. 2020;83(6):1838\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"730_CR59","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/PRS.0b013e3181ef816d","volume":"126","author":"BJ Freund","year":"2010","unstructured":"Freund BJ, Schwartz M. Treatment of male pattern baldness with botulinum toxin: a pilot study. Plast Reconstr Surg. 2010;126(5):246\u20138.","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"730_CR60","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/JCAS.JCAS_77_17","volume":"10","author":"S Singh","year":"2017","unstructured":"Singh S, Neema S, Vasudevan B. A pilot study to evaluate effectiveness of botulinum toxin in treatment of androgenetic alopecia in males. J Cutan Aesthet Surg. 2017;10(3):163.","journal-title":"J Cutan Aesthet Surg"},{"issue":"11","key":"730_CR61","doi-asserted-by":"publisher","first-page":"e492","DOI":"10.1111\/jdv.14336","volume":"31","author":"J Bharti","year":"2017","unstructured":"Bharti J, Sonthalia S, Patil P, Dhurat R. Scalp threading with polydioxanone monofilament threads: a novel, effective and safe modality for hair restoration. J Eur Acad Dermatol Venereol. 2017;31(11):e492\u20133.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00730-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00730-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T08:11:47Z","timestamp":1675325507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00730-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00730-y","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]},"assertion":[{"value":"6 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RG, SV-G, and DS-C designed the article and DS-C wrote the majority of the article. MD-S corrected and supervised the information and RG undertook the final corrections.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"No sources of funding were received to assist in the preparation of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"David Saceda-Corralo, Miguel Dom\u00ednguez-Santas, Sergio Va\u00f1\u00f3-Galv\u00e1n, and Ram\u00f3n Grimalt have no conflicts of interest in relation to the subject matter of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This was a review and hence ethical approval was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}